COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Their focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Currently, COMPASS is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD). COMPASS is headquartered in London, UK, with offices in New York, USA.
Stock Performance
COMPASS Pathways News 98 articles
- Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
- Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
- 2026 Mid-Year Psychedelic Industry Report
- Compass Pathways reports six-month Phase 3 COMP006 data confirming durable psilocybin response
- Compass reports Q1 2026 results with $466 million cash position
- Compass sets May 13 date for first-quarter 2026 results
- FDA grants Compass rolling NDA review and a National Priority Voucher for COMP360
- Compass commends White House psychedelics executive order
- Compass opens U.S. grant program to build COMP360 provider training
- 2026 Q1 Psychedelic Industry Report
- Compass reports 2025 results, says cash runway extends into 2028
- Compass prices $150 million public offering on the heels of Phase 3 data
- Compass hits primary endpoint in second Phase 3 psilocybin trial, giving it two positive pivotal studies
- Trump administration officials strip Compass psilocybin from FDA fast-track voucher list
- FDA accepts Compass Pathways' IND for COMP360 psilocybin in PTSD
- Compass accelerates commercial launch plans by 9-12 months in Q3 update
- 2025 Q3 Psychedelic Industry Report
- Compass publishes Phase 2 results for COMP360 psilocybin in PTSD
- Compass Pathways posts Q2 2025 results and weighs an accelerated COMP360 filing
- Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
- Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
- Compass Pathways Streamlines Operations with Workforce Reduction and Shift in Research Focus
- Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
- Is Compass Pathways Poised for Success?
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
- Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
- Compass Pathways Lost Its Co-Founders – Now What?
- Compass Pathways To Participate in Upcoming 23rd Annual Needham Virtual Healthcare Conference
- Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
- COMPASS Pathways appoints Daphne Karydas to its Board of Directors
- Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester
- COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
- COMPASS Pathways To Participate in Upcoming September Investor Conferences
- COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
- COMPASS Pathways Financial Analysis: Road to Profitability
- COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
- COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
- First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
- COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
- Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
Showing the 40 most recent of 98 articles.